Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)

US9816080B2 · kind B2 · utility

Assignees

• President and Fellows of Harvard College · US
• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Quan Lu · Shanghai, CN
• Qiyu Wang · Boston, US
• Stanley N. Cohen · Stanford, US

Key dates

• Filing date: Oct 30, 2015
• Grant date: Nov 14, 2017
• Expiry date: Oct 30, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2810/85
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.